Related references
Note: Only part of the references are listed.AASLD guidelines for treatment of chronic hepatitis B
Norah A. Terrault et al.
HEPATOLOGY (2016)
Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients
W. P. Brouwer et al.
JOURNAL OF VIRAL HEPATITIS (2016)
Letter: nucleos(t)ide analogues are good, but not sufficient for hepatitis B virus clearance
M. Afyon
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin et al.
GASTROENTEROLOGY (2016)
Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B
M. -L. Chang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides
V. R. Patwardhan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-alpha 2a and adefovir
R. Bart Takkenberg et al.
ANTIVIRAL THERAPY (2013)
Response-Guided Peginterferon Therapy in Hepatitis B e Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels
Milan J. Sonneveld et al.
HEPATOLOGY (2013)
Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients
Teerha Piratvisuth et al.
HEPATOLOGY INTERNATIONAL (2013)
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
Patrick Marcellin et al.
HEPATOLOGY INTERNATIONAL (2013)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2012)
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
Vincent Rijckborst et al.
JOURNAL OF HEPATOLOGY (2012)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2012)
Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B
H. L. -Y. Chan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Early On-Treatment Prediction of Response to Peginterferon Alfa-2a for HBeAg-Negative Chronic Hepatitis B Using HBsAg and HBV DNA Levels
Vincent Rijckborst et al.
HEPATOLOGY (2010)
Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen Positive Chronic Hepatitis B Using On-Treatment Hepatitis B Surface Antigen Decline
Milan J. Sonneveld et al.
HEPATOLOGY (2010)
Early Serum HBsAg Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients
Rami Moucari et al.
HEPATOLOGY (2009)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
F. Bonino et al.
GUT (2007)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
